As a group we can achieve more than we can individually, said Dragnev of the co-operative groups in the nationwide network. Urban and rural residents can participate in the same study, which expands our ability to include a more diverse population in an individual study. The Dartmouth-led affiliations also mean greater access to new therapies in relatively remote areas served in northern New England.
The new network represents an unmatched effort to integrate and streamline the process of cancer clinical trials research, said James Doroshow, MD, deputy director for clinical and translational research at NCI. The conduct of NCI-supported trials, which are publicly funded, involves a complex system of designing, reviewing, and initiating studies. The new NCTN replaces a structure that was more than 55 years old.
NCTN employs an inclusive process for generating studies and conducting clinical trials using broad representation from the oncology field, including academic researchers, as well as professional organizations, patients, and advocates.
The Network has combined smaller cooperative groups with specialized foci, such as, pediatric, breast/bowel, or gynecological cancers. These consolidated cooperative groups allow for closer communication and collaboration among researchers doing work in the same area. The newly announced Lead Academic Participating Sites will serve as common outlets for offering trials originating from any of these groups.
Norris Cotton Cancer Centers selection as a Lead Participating Site affirms our role as a national leader in cancer research, said Mark Israel, MD, director, Norris Cotton Cancer Center. We are among an elite group of invest
|Contact: Donna Dubuc|
The Geisel School of Medicine at Dartmouth